NECC's Conigliaro Faces New Probe

By Walter F. Roche Jr.

A part owner of a defunct drug compounding company is facing a probe from a Massachusetts regulatory board that could place his real estate license in jeopardy.
The Massachusetts Board of Real Estate Brokers and Salesmen voted this week to open an investigation into Gregory Conigliaro, who already is facing sentencing following his conviction on federal charges that he conspired to defraud the U.S. Food and Drug Administration.
Conigliaro was part owner of the New England Compounding Center, the company blamed for a deadly 2012 fungal meningitis outbreak.
Conigliaro was granted a real estate salesman's license by the Massachusetts board in early December of 2014, just weeks before he and 13 others were indicted by a federal grand jury following a two year probe of the outbreak.
His license as a salesman was issued Dec. 7, 2014 and is due to expire on Nov. 24, 2020
Four other NECC defendants, who were convicted late last year, already were facing investigations by the Massachusetts Board of Pharmacy. Those defendants were licensed as pharmacists or pharmacy technicians.
Gene Svirskiy, Christopher Leary, Alla Stepanets and Sharon Carter were convicted on charges ranging from racketeering to conspiracy and mail fraud. Joseph Evanosky, a pharmacist and former NECC employee who was also indicted, was cleared of charges and is not subject to a pharmacy board inquiry.
Leary, Svirskiy and Stepanets are licensed pharmacists, while Carter is a registered pharmacy technician.
Conigliaro has filed a motion asking U.S. District Judge Richard G. Stearns to overturn the jury's guilty verdict. A hearing on that motion and a similar motion filed by Carter is scheduled for Feb. 26.
Conigliaro was a 10 percent owner of NECC and a sister firm, Ameridose. Prosecutors were barred from telling jurors during the 2018 trial that he earned some $20 million from the two firms over a six year period. Like NECC Ameridose was shutdown in late 2012.
Contact: wfrochejr999@gmail.com